Literature DB >> 21225946

Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success.

Thomas P Lodise1, Jill Butterfield.   

Abstract

Dose optimization is one of the key strategies for enhancing antimicrobial stewardship. There have been tremendous strides in our understanding of antibiotic exposure-response relationships over the past 25 years. For many antibiotics, the "pharmacodynamic" or the exposure variable associated with outcome has been identified. With advances in mathematical modeling, it is possible to apply our understanding of antimicrobial pharmacodynamics (PD) into clinical practice and design empirical regimens that have a high probability of achieving the PD target linked to effect. By optimizing antibiotic doses to achieve PD targets predictive of efficacy, clinicians can improve care and minimize drug toxicity. For β-lactams, the PD parameter most predictive of maximal bactericidal activity is the duration of time free drug concentrations remain above the minimum inhibitory concentration (MIC) during the dosing interval (fT > MIC). Unfortunately, the conventional intermittent β-lactam dosing schemes often used in practice have suboptimal PD profiles. Prolonging the infusion time of β-lactams is one method to maximize the probability of achieving concentrations in excess of the MIC for the majority of the dosing interval, especially against pathogens with elevated MIC values. Prolonged infusions of intravenous β-lactams are not only associated with improved probability of target attainment (PTA) profiles but offer possible cost savings and greater potential for reducing emergence of resistance relative to intermittent infusions.
Copyright © 2011 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225946     DOI: 10.1002/jhm.869

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  10 in total

1.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Robert W Kulawy; Rachid Daoui; Joseph Roglieri; Shari Meola; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 3.  [Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-09-13       Impact factor: 0.840

Review 4.  Bacterial sepsis : Diagnostics and calculated antibiotic therapy.

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Kruger; K Mayer; M W Pletz; D Storzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

Review 5.  [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Krüger; K Mayer; M W Pletz; D Störzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; Christoph Lichtenstern
Journal:  Anaesthesist       Date:  2017-10       Impact factor: 1.041

Review 6.  Year in review 2010: Critical Care--Infection.

Authors:  Leonardo Pagani; Arash Afshari; Stephan Harbarth
Journal:  Crit Care       Date:  2011-12-05       Impact factor: 9.097

7.  Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.

Authors:  Adriana Tremoulet; Jennifer Le; Brenda Poindexter; Janice E Sullivan; Matthew Laughon; Paula Delmore; Andrea Salgado; Sandy Ian-U Chong; Chiara Melloni; Jamie Gao; Daniel K Benjamin; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.938

Review 8.  Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction.

Authors:  Ijaz Ahmad; Lingli Huang; Haihong Hao; Pascal Sanders; Zonghui Yuan
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

9.  Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat.

Authors:  Valentina Selmi; Beatrice Loriga; Luca Vitali; Martina Carlucci; Alessandro Di Filippo; Giulio Carta; Eleonora Sgambati; Lorenzo Tofani; Angelo Raffaele De Gaudio; Andrea Novelli; Chiara Adembri
Journal:  J Transl Med       Date:  2016-11-15       Impact factor: 5.531

10.  Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.

Authors:  Paul Chabert; Judith Provoost; Sabine Cohen; Céline Dupieux-Chabert; Laurent Bitker; Tristan Ferry; Sylvain Goutelle; Jean-Christophe Richard
Journal:  Ann Intensive Care       Date:  2022-09-30       Impact factor: 10.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.